Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Regulatory inspections increasingly reveal that quality failures stem from governance and oversight gaps, not technical errors. This article explains how quality systems, documentation, and inspection readiness shape compliance outcomes in regulated pharmaceutical manufacturing environments.
EMA nitrosamine Appendix 1 has reshaped how inspectors assess risk, justification, and lifecycle oversight. This article explains what regulators review during GMP inspections, how expectations apply in practice, and why governance gaps often escalate nitrosamine-related findings.